Proteomic Analysis of the Low Molecular Mass Fraction of Newly Diagnosed and Recurrent Glioblastoma CUSA Fluid: A Pilot Investigation of the Peptidomic Profile
Authors:
- Alexandra MuntiuAlexandra Muntiu
- Federica VincenzoniFVFederica Vincenzoni
- Diana Valeria RossettiDRDiana Valeria Rossetti
- Andrea UrbaniAUAndrea Urbani
- Giuseppe La RoccaGiuseppe La Rocca
- Alessio AlbaneseAAAlessio Albanese
- Edoardo MazzucchiEMEdoardo Mazzucchi
- Alessandro OliviAOAlessandro Olivi
- Giovanni SabatinoGSGiovanni Sabatino
- Claudia DesiderioCDClaudia Desiderio
Open Access
- 24 June 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6055
Abstract
Glioblastoma multiforme (GBM) is a highly aggressive, treatment-resistant grade IV brain tumor with poor prognosis that grows rapidly and invades surrounding tissues, complicating surgery and frequently recurring. Although the crucial role of endogenous peptides has been highlighted for several tumors, the specific peptidomic profile of GBM remains unexplored to date. This study aimed to perform a preliminary characterization of the low molecular mass proteome fraction of Cavitron Ultrasonic Surgical Aspirator (CUSA) fluid collected from different tumor zones, i.e., the core and tumor periphery of newly diagnosed (ND) and recurrent (R) GBM. The samples, pooled by tumor type and collection zone, were centrifuged through molecular cut-off filter devices to collect the non-retained fraction of the proteome <10 kDa for direct full-length LC-MS analysis. A total of 40 and 24 peptides, fragments of 32 and 18 proteins, were marked as ND and R GBM COREs, respectively, while 132 peptides, fragments of 46 precursor proteins, were identified as common and included proteins which were cancer-related or involved in GBM pathophysiology. Besides providing a preliminary overview of the unexplored peptidome of GBM, this pilot study confirms peptidomics as a promising tool to discover potential GBM biomarkers in the perspective of clinical applications increasingly oriented towards a precision medicine approach. Data are available via ProteomeXchange with the identifier PXD060807.Keywords
This publication has 90 references indexed in Scilit:
- Glioma and post-translational modifications: A complex relationshipBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023
- Vimentin promotes glioma progression and maintains glioma cell resistance to oxidative phosphorylation inhibitionCellular Oncology, 2023
- The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory driversActa Neuropathologica, 2022
- Protein phosphorylation: A potential target in glioma developmentIbrain, 2022
- 5-ALA and FDA approval for glioma surgeryJournal of Neuro-Oncology, 2019
- Understanding the Role of ApoE Fragments in Alzheimer’s DiseaseNeurochemical Research, 2018
- Integrated analysis of proteome, phosphotyrosine‐proteome, tyrosine‐kinome, and tyrosine‐phosphatome in acute myeloid leukemiaProteomics, 2017
- Nestin Expression Is Associated with Poor Clinicopathological Features and Prognosis in Glioma Patients: an Association Study and Meta-analysisMolecular Neurobiology, 2016
- Cell surface Nestin is a biomarker for glioma stem cellsBiochemical and Biophysical Research Communications, 2013
- HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesisJournal of Neuro-Oncology, 2011